Candriam S.C.A. Protagonist Therapeutics, Inc Transaction History
Candriam S.C.A.
- $16.3 Billion
- Q2 2024
A detailed history of Candriam S.C.A. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Candriam S.C.A. holds 273,818 shares of PTGX stock, worth $12.6 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
273,818
Previous 360,000
23.94%
Holding current value
$12.6 Million
Previous $10.4 Million
8.9%
% of portfolio
0.06%
Previous 0.07%
Shares
8 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$268 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$242 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$152 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$149 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.25B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...